Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Embolization, Therapeutic | 16 | 2024 | 227 | 4.060 |
Why?
|
Hematoma, Subdural, Chronic | 7 | 2024 | 9 | 3.090 |
Why?
|
Thrombectomy | 17 | 2024 | 103 | 2.690 |
Why?
|
Bone Screws | 8 | 2015 | 51 | 2.210 |
Why?
|
Atlanto-Axial Joint | 8 | 2015 | 21 | 1.870 |
Why?
|
Meningeal Arteries | 8 | 2024 | 11 | 1.850 |
Why?
|
Tinnitus | 2 | 2023 | 19 | 1.660 |
Why?
|
Stroke | 17 | 2024 | 957 | 1.640 |
Why?
|
Intracranial Aneurysm | 8 | 2022 | 93 | 1.480 |
Why?
|
Endovascular Procedures | 10 | 2024 | 731 | 1.200 |
Why?
|
Neurosurgical Procedures | 6 | 2020 | 299 | 1.170 |
Why?
|
Treatment Outcome | 45 | 2024 | 12168 | 1.060 |
Why?
|
Cranial Sinuses | 2 | 2023 | 12 | 1.040 |
Why?
|
Stents | 11 | 2024 | 878 | 1.040 |
Why?
|
Magnesium Sulfate | 1 | 2024 | 50 | 0.930 |
Why?
|
Cervical Vertebrae | 2 | 2015 | 107 | 0.910 |
Why?
|
Neuroprotective Agents | 1 | 2024 | 150 | 0.850 |
Why?
|
Drainage | 2 | 2016 | 257 | 0.850 |
Why?
|
Cerebral Revascularization | 3 | 2023 | 21 | 0.830 |
Why?
|
Constriction, Pathologic | 7 | 2023 | 240 | 0.820 |
Why?
|
Spinal Fusion | 7 | 2018 | 107 | 0.720 |
Why?
|
Brain Ischemia | 5 | 2023 | 258 | 0.700 |
Why?
|
Craniotomy | 3 | 2016 | 108 | 0.640 |
Why?
|
Aged | 34 | 2024 | 19173 | 0.640 |
Why?
|
Cervical Atlas | 2 | 2016 | 8 | 0.640 |
Why?
|
Retrospective Studies | 35 | 2024 | 16066 | 0.630 |
Why?
|
Middle Aged | 39 | 2024 | 26075 | 0.630 |
Why?
|
Joint Instability | 3 | 2013 | 42 | 0.620 |
Why?
|
Cerebral Hemorrhage | 4 | 2023 | 144 | 0.610 |
Why?
|
Aged, 80 and over | 20 | 2024 | 6387 | 0.610 |
Why?
|
Vertebral Artery | 3 | 2014 | 24 | 0.600 |
Why?
|
Angioplasty | 4 | 2024 | 85 | 0.580 |
Why?
|
Humans | 77 | 2024 | 123305 | 0.580 |
Why?
|
Non-alcoholic Fatty Liver Disease | 1 | 2022 | 389 | 0.550 |
Why?
|
Propensity Score | 4 | 2024 | 212 | 0.530 |
Why?
|
Neurosurgery | 2 | 2014 | 76 | 0.530 |
Why?
|
Arthrodesis | 2 | 2015 | 14 | 0.530 |
Why?
|
Hematoma, Subdural | 1 | 2016 | 20 | 0.520 |
Why?
|
Tranexamic Acid | 1 | 2016 | 19 | 0.520 |
Why?
|
Antifibrinolytic Agents | 1 | 2016 | 33 | 0.510 |
Why?
|
Anticoagulants | 3 | 2023 | 581 | 0.470 |
Why?
|
Orthopedic Procedures | 1 | 2015 | 68 | 0.460 |
Why?
|
Spinal Injuries | 1 | 2013 | 29 | 0.430 |
Why?
|
Aneurysm, Ruptured | 2 | 2015 | 36 | 0.430 |
Why?
|
Arachnoid | 2 | 2023 | 8 | 0.430 |
Why?
|
Male | 42 | 2024 | 60282 | 0.430 |
Why?
|
Carotid Artery Diseases | 1 | 2014 | 147 | 0.420 |
Why?
|
Tomography, X-Ray Computed | 6 | 2024 | 2058 | 0.420 |
Why?
|
Female | 43 | 2024 | 65618 | 0.420 |
Why?
|
Prostheses and Implants | 1 | 2014 | 150 | 0.410 |
Why?
|
Betacoronavirus | 3 | 2020 | 286 | 0.400 |
Why?
|
Spinal Cord | 2 | 2021 | 305 | 0.400 |
Why?
|
Heparin | 1 | 2013 | 227 | 0.390 |
Why?
|
Arteries | 1 | 2012 | 222 | 0.370 |
Why?
|
Aneurysm, False | 1 | 2012 | 102 | 0.360 |
Why?
|
Congenital Abnormalities | 1 | 2014 | 255 | 0.360 |
Why?
|
Vascular Diseases | 1 | 2012 | 164 | 0.360 |
Why?
|
Venous Thromboembolism | 1 | 2013 | 161 | 0.360 |
Why?
|
Surgeons | 1 | 2015 | 247 | 0.360 |
Why?
|
Coronavirus Infections | 3 | 2020 | 358 | 0.350 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 374 | 0.350 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 625 | 0.340 |
Why?
|
Middle Cerebral Artery | 3 | 2021 | 110 | 0.340 |
Why?
|
Registries | 6 | 2024 | 1397 | 0.320 |
Why?
|
Delivery of Health Care | 1 | 2014 | 606 | 0.300 |
Why?
|
Adult | 18 | 2023 | 29087 | 0.300 |
Why?
|
Subarachnoid Hemorrhage | 2 | 2022 | 73 | 0.290 |
Why?
|
Angiography | 2 | 2020 | 215 | 0.270 |
Why?
|
Anesthesia, General | 2 | 2024 | 112 | 0.260 |
Why?
|
Blood Vessel Prosthesis | 3 | 2020 | 534 | 0.250 |
Why?
|
Recovery of Function | 2 | 2024 | 437 | 0.230 |
Why?
|
Radiosurgery | 2 | 2016 | 106 | 0.230 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2024 | 32 | 0.230 |
Why?
|
Reperfusion | 2 | 2020 | 25 | 0.230 |
Why?
|
Carotid Artery, Internal | 3 | 2024 | 68 | 0.220 |
Why?
|
Skull | 3 | 2023 | 141 | 0.210 |
Why?
|
Blood Coagulation Disorders | 1 | 2024 | 100 | 0.210 |
Why?
|
Moyamoya Disease | 1 | 2023 | 38 | 0.210 |
Why?
|
Vasospasm, Intracranial | 1 | 2022 | 18 | 0.200 |
Why?
|
Balloon Embolectomy | 2 | 2018 | 2 | 0.200 |
Why?
|
Drug-Eluting Stents | 1 | 2023 | 55 | 0.200 |
Why?
|
Fetal Stem Cells | 2 | 2012 | 5 | 0.200 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2021 | 9 | 0.190 |
Why?
|
Maternal-Fetal Exchange | 2 | 2012 | 80 | 0.190 |
Why?
|
Urinary Retention | 1 | 2021 | 18 | 0.190 |
Why?
|
Radiology, Interventional | 1 | 2021 | 28 | 0.190 |
Why?
|
Central Nervous System Vascular Malformations | 1 | 2021 | 19 | 0.190 |
Why?
|
Arterial Occlusive Diseases | 1 | 2022 | 127 | 0.190 |
Why?
|
Ischemic Attack, Transient | 1 | 2021 | 55 | 0.190 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2012 | 104 | 0.180 |
Why?
|
Temporal Arteries | 1 | 2021 | 41 | 0.180 |
Why?
|
New York City | 4 | 2021 | 57 | 0.180 |
Why?
|
Time-to-Treatment | 4 | 2024 | 186 | 0.180 |
Why?
|
Pandemics | 4 | 2021 | 1101 | 0.180 |
Why?
|
Brain Infarction | 1 | 2020 | 30 | 0.180 |
Why?
|
Hemangioma, Cavernous, Central Nervous System | 1 | 2020 | 17 | 0.180 |
Why?
|
Pons | 1 | 2020 | 32 | 0.180 |
Why?
|
Comprehensive Health Care | 1 | 2020 | 18 | 0.170 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2020 | 31 | 0.170 |
Why?
|
Carotid Stenosis | 1 | 2021 | 133 | 0.170 |
Why?
|
Fibrinolytic Agents | 1 | 2022 | 198 | 0.170 |
Why?
|
Brain Neoplasms | 2 | 2022 | 1236 | 0.170 |
Why?
|
Skull Base | 2 | 2020 | 54 | 0.170 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 41 | 0.170 |
Why?
|
Empirical Research | 1 | 2019 | 9 | 0.170 |
Why?
|
Spinal Cord Diseases | 1 | 2020 | 40 | 0.170 |
Why?
|
Arteriovenous Malformations | 1 | 2020 | 46 | 0.170 |
Why?
|
Arteriovenous Fistula | 1 | 2020 | 56 | 0.160 |
Why?
|
Neoplasms | 1 | 2014 | 2757 | 0.160 |
Why?
|
Glioblastoma | 1 | 2022 | 334 | 0.160 |
Why?
|
Cerebrovascular Disorders | 1 | 2019 | 117 | 0.160 |
Why?
|
Catheters | 3 | 2024 | 89 | 0.160 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 123 | 0.160 |
Why?
|
Hyperglycemia | 1 | 2020 | 222 | 0.160 |
Why?
|
Thrombolytic Therapy | 1 | 2020 | 204 | 0.150 |
Why?
|
Biomechanical Phenomena | 2 | 2018 | 244 | 0.150 |
Why?
|
Spinal Diseases | 1 | 2018 | 46 | 0.150 |
Why?
|
Quality Indicators, Health Care | 1 | 2020 | 214 | 0.150 |
Why?
|
Glioma | 1 | 2022 | 496 | 0.150 |
Why?
|
Combined Modality Therapy | 2 | 2024 | 1239 | 0.150 |
Why?
|
Lumbar Vertebrae | 1 | 2018 | 109 | 0.150 |
Why?
|
Confidence Intervals | 2 | 2014 | 279 | 0.140 |
Why?
|
Time Factors | 5 | 2024 | 6228 | 0.140 |
Why?
|
Neuroendoscopy | 1 | 2016 | 26 | 0.130 |
Why?
|
Epidermal Cyst | 1 | 2016 | 19 | 0.130 |
Why?
|
Nervous System Neoplasms | 1 | 2016 | 11 | 0.130 |
Why?
|
Intracranial Arteriovenous Malformations | 1 | 2016 | 28 | 0.130 |
Why?
|
Blood Glucose | 1 | 2020 | 1122 | 0.130 |
Why?
|
Finite Element Analysis | 1 | 2016 | 28 | 0.130 |
Why?
|
Dermoid Cyst | 1 | 2016 | 34 | 0.130 |
Why?
|
Epilepsy | 2 | 2016 | 858 | 0.130 |
Why?
|
Health Personnel | 1 | 2020 | 493 | 0.120 |
Why?
|
Carotid-Cavernous Sinus Fistula | 1 | 2015 | 9 | 0.120 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 1084 | 0.120 |
Why?
|
Printing, Three-Dimensional | 1 | 2016 | 68 | 0.120 |
Why?
|
Models, Anatomic | 1 | 2016 | 98 | 0.120 |
Why?
|
Vascular Access Devices | 1 | 2015 | 35 | 0.120 |
Why?
|
Case-Control Studies | 1 | 2022 | 3240 | 0.120 |
Why?
|
Tuberous Sclerosis | 1 | 2016 | 121 | 0.120 |
Why?
|
Quality Improvement | 1 | 2020 | 626 | 0.120 |
Why?
|
Young Adult | 5 | 2016 | 8871 | 0.120 |
Why?
|
Vascular Patency | 1 | 2015 | 204 | 0.110 |
Why?
|
Patients | 1 | 2015 | 121 | 0.110 |
Why?
|
Thrombosis | 1 | 2018 | 520 | 0.110 |
Why?
|
Computer-Assisted Instruction | 1 | 2014 | 51 | 0.110 |
Why?
|
Intention to Treat Analysis | 2 | 2024 | 58 | 0.110 |
Why?
|
Hydrocephalus | 1 | 2016 | 242 | 0.110 |
Why?
|
Cadaver | 1 | 2013 | 129 | 0.110 |
Why?
|
Physician's Role | 1 | 2015 | 165 | 0.110 |
Why?
|
Osteoarthritis, Spine | 1 | 2012 | 2 | 0.100 |
Why?
|
Data Collection | 1 | 2015 | 384 | 0.100 |
Why?
|
Sex Distribution | 1 | 2013 | 294 | 0.100 |
Why?
|
Age Distribution | 1 | 2013 | 410 | 0.100 |
Why?
|
Alberta | 2 | 2023 | 43 | 0.100 |
Why?
|
Braces | 1 | 2012 | 14 | 0.100 |
Why?
|
Arachnoid Cysts | 1 | 2012 | 8 | 0.100 |
Why?
|
Coronary Artery Disease | 1 | 2018 | 750 | 0.100 |
Why?
|
Thoracic Vertebrae | 1 | 2012 | 66 | 0.100 |
Why?
|
Radiography | 1 | 2014 | 822 | 0.100 |
Why?
|
Hospitalization | 2 | 2020 | 1739 | 0.100 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 420 | 0.100 |
Why?
|
Terminology as Topic | 1 | 2013 | 229 | 0.100 |
Why?
|
Imaging, Three-Dimensional | 1 | 2014 | 361 | 0.100 |
Why?
|
Pilot Projects | 1 | 2016 | 1390 | 0.100 |
Why?
|
Preoperative Care | 1 | 2014 | 349 | 0.090 |
Why?
|
Pain | 1 | 2015 | 470 | 0.090 |
Why?
|
Hypothalamic Diseases | 1 | 2012 | 37 | 0.090 |
Why?
|
Hamartoma | 1 | 2012 | 52 | 0.090 |
Why?
|
Wounds and Injuries | 1 | 2015 | 364 | 0.090 |
Why?
|
Risk | 1 | 2013 | 747 | 0.090 |
Why?
|
Stem Cell Transplantation | 1 | 2012 | 238 | 0.090 |
Why?
|
Vagus Nerve Stimulation | 1 | 2011 | 52 | 0.090 |
Why?
|
Animals | 5 | 2024 | 33817 | 0.090 |
Why?
|
Severity of Illness Index | 2 | 2020 | 2852 | 0.090 |
Why?
|
Abnormalities, Multiple | 1 | 2016 | 962 | 0.080 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 642 | 0.080 |
Why?
|
Education, Medical, Graduate | 1 | 2014 | 507 | 0.080 |
Why?
|
Myocardial Ischemia | 1 | 2012 | 332 | 0.080 |
Why?
|
Adolescent | 4 | 2016 | 19132 | 0.080 |
Why?
|
Cell Movement | 1 | 2011 | 831 | 0.070 |
Why?
|
Prevalence | 1 | 2013 | 2407 | 0.070 |
Why?
|
Myocardium | 1 | 2011 | 986 | 0.070 |
Why?
|
Cerebral Angiography | 2 | 2018 | 102 | 0.070 |
Why?
|
Child | 6 | 2016 | 24264 | 0.060 |
Why?
|
Infarction, Anterior Cerebral Artery | 1 | 2024 | 2 | 0.060 |
Why?
|
Vertebrobasilar Insufficiency | 1 | 2024 | 5 | 0.060 |
Why?
|
Myocardial Infarction | 1 | 2011 | 1003 | 0.060 |
Why?
|
Cell Differentiation | 1 | 2011 | 1909 | 0.060 |
Why?
|
Internship and Residency | 1 | 2014 | 1159 | 0.050 |
Why?
|
Treatment Failure | 1 | 2024 | 336 | 0.050 |
Why?
|
Polymethyl Methacrylate | 1 | 2023 | 24 | 0.050 |
Why?
|
United States | 2 | 2020 | 10667 | 0.050 |
Why?
|
Cerebral Infarction | 1 | 2023 | 46 | 0.050 |
Why?
|
Anterior Cerebral Artery | 1 | 2022 | 8 | 0.050 |
Why?
|
Cytoreduction Surgical Procedures | 1 | 2022 | 30 | 0.050 |
Why?
|
Dilatation | 1 | 2022 | 68 | 0.050 |
Why?
|
Intracranial Hemorrhages | 1 | 2022 | 73 | 0.050 |
Why?
|
Retreatment | 1 | 2022 | 88 | 0.050 |
Why?
|
Walruses | 1 | 2021 | 1 | 0.050 |
Why?
|
Paraparesis | 1 | 2021 | 11 | 0.050 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2024 | 258 | 0.050 |
Why?
|
Postoperative Complications | 1 | 2014 | 3020 | 0.050 |
Why?
|
Disease Models, Animal | 1 | 2012 | 4289 | 0.050 |
Why?
|
Prospective Studies | 2 | 2023 | 6032 | 0.050 |
Why?
|
Biomarkers | 2 | 2020 | 2948 | 0.050 |
Why?
|
Carotid Artery, Common | 1 | 2021 | 73 | 0.050 |
Why?
|
Vasodilator Agents | 1 | 2022 | 204 | 0.050 |
Why?
|
Cranial Fossa, Posterior | 1 | 2020 | 14 | 0.050 |
Why?
|
Constipation | 1 | 2021 | 113 | 0.040 |
Why?
|
Green Fluorescent Proteins | 2 | 2012 | 394 | 0.040 |
Why?
|
Cerebral Small Vessel Diseases | 1 | 2020 | 10 | 0.040 |
Why?
|
Blood Sedimentation | 1 | 2020 | 28 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 35 | 0.040 |
Why?
|
Causality | 1 | 2020 | 83 | 0.040 |
Why?
|
Radial Artery | 1 | 2020 | 26 | 0.040 |
Why?
|
Troponin | 1 | 2020 | 71 | 0.040 |
Why?
|
Thrombophilia | 1 | 2020 | 41 | 0.040 |
Why?
|
Prone Position | 1 | 2020 | 32 | 0.040 |
Why?
|
Critical Pathways | 1 | 2020 | 68 | 0.040 |
Why?
|
Workflow | 1 | 2020 | 114 | 0.040 |
Why?
|
Operating Rooms | 1 | 2020 | 71 | 0.040 |
Why?
|
Personal Protective Equipment | 1 | 2020 | 54 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 3547 | 0.040 |
Why?
|
Patient Positioning | 1 | 2020 | 54 | 0.040 |
Why?
|
Monitoring, Intraoperative | 1 | 2020 | 128 | 0.040 |
Why?
|
Patient Admission | 1 | 2020 | 184 | 0.040 |
Why?
|
Aphasia | 1 | 2018 | 14 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2021 | 756 | 0.040 |
Why?
|
Endoscopy | 1 | 2020 | 282 | 0.040 |
Why?
|
Ultrasonography | 1 | 2023 | 942 | 0.040 |
Why?
|
Range of Motion, Articular | 1 | 2018 | 73 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2018 | 5050 | 0.040 |
Why?
|
Neuroimaging | 1 | 2020 | 332 | 0.040 |
Why?
|
Recurrence | 1 | 2020 | 1419 | 0.030 |
Why?
|
Brain | 2 | 2022 | 2967 | 0.030 |
Why?
|
Risk Factors | 2 | 2020 | 10042 | 0.030 |
Why?
|
Patient Care Team | 1 | 2020 | 549 | 0.030 |
Why?
|
Disease Progression | 1 | 2022 | 2031 | 0.030 |
Why?
|
Survival Rate | 1 | 2020 | 2001 | 0.030 |
Why?
|
Comorbidity | 1 | 2020 | 1498 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2016 | 121 | 0.030 |
Why?
|
Cohort Studies | 1 | 2024 | 4709 | 0.030 |
Why?
|
Graft Occlusion, Vascular | 1 | 2015 | 95 | 0.030 |
Why?
|
Cerebral Arteries | 1 | 2015 | 79 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 1877 | 0.030 |
Why?
|
Zygapophyseal Joint | 1 | 2012 | 4 | 0.030 |
Why?
|
Neck Pain | 1 | 2012 | 19 | 0.030 |
Why?
|
Incidence | 1 | 2020 | 3052 | 0.030 |
Why?
|
CDX2 Transcription Factor | 1 | 2011 | 8 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2012 | 458 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 228 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2011 | 311 | 0.020 |
Why?
|
Headache | 1 | 2012 | 108 | 0.020 |
Why?
|
Infant | 2 | 2016 | 12379 | 0.020 |
Why?
|
Calcinosis | 1 | 2012 | 170 | 0.020 |
Why?
|
Child, Preschool | 2 | 2016 | 13916 | 0.020 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2011 | 239 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2011 | 967 | 0.020 |
Why?
|
Vision Disorders | 1 | 2012 | 210 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2012 | 804 | 0.020 |
Why?
|
Models, Animal | 1 | 2011 | 464 | 0.020 |
Why?
|
Reoperation | 1 | 2012 | 819 | 0.020 |
Why?
|
Pregnancy | 2 | 2012 | 7156 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2011 | 516 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2011 | 544 | 0.020 |
Why?
|
Biopsy | 1 | 2012 | 1236 | 0.020 |
Why?
|
Anticonvulsants | 1 | 2011 | 376 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2011 | 1313 | 0.020 |
Why?
|
Myocytes, Cardiac | 1 | 2011 | 618 | 0.020 |
Why?
|
Electroencephalography | 1 | 2011 | 857 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2011 | 2396 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2011 | 3043 | 0.020 |
Why?
|
Mice | 2 | 2012 | 17546 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2016 | 8118 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2012 | 4357 | 0.010 |
Why?
|
Transcription Factors | 1 | 2011 | 2587 | 0.010 |
Why?
|